Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

103.17
+1.391.37%
Post-market: 103.170.00000.00%19:52 EDT
Volume:94.74K
Turnover:9.75M
Market Cap:4.35B
PE:-100.33
High:103.36
Open:101.87
Low:101.75
Close:101.78
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:0.59
T/O Rate:0.22%
Dividend:1.38
Dividend Rate:1.33%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.12
PE(LYR):-100.33

Loading ...

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
Oct 06

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
Oct 06

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Oct 06

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Sector Update: Healthcare Stocks Rise Monday Afternoon

MT Newswires Live
·
Oct 06

Mediobanca Steps Up Trading Activity in Listed Shares of Philogen

TIPRANKS
·
Oct 06

Emeis Executes Share Buyback as Mission-Driven Care Group Expands Role in Vulnerable Healthcare

TIPRANKS
·
Oct 06

FTC issues letters warning hospitals against ‘deceptive’ pricing practices

TIPRANKS
·
Oct 06